1
|
Hindré R, Besnard V, Kort F, Nunes H, Valeyre D, Jeny F. Complete response to mTOR inhibitor following JAKi failure in severe pulmonary sarcoidosis. Pulmonology 2024:S2531-0437(24)00042-4. [PMID: 38614861 DOI: 10.1016/j.pulmoe.2024.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2024] [Revised: 03/18/2024] [Accepted: 03/19/2024] [Indexed: 04/15/2024] Open
Affiliation(s)
- R Hindré
- AP-HP, Pulmonology Departement, Avicenne Hospital, Bobigny, France; Inserm UMR 1272, Sorbonne Paris Nord University, Bobigny, France.
| | - V Besnard
- Inserm UMR 1272, Sorbonne Paris Nord University, Bobigny, France
| | - F Kort
- AP-HP, Pulmonology Departement, Avicenne Hospital, Bobigny, France
| | - H Nunes
- AP-HP, Pulmonology Departement, Avicenne Hospital, Bobigny, France; Inserm UMR 1272, Sorbonne Paris Nord University, Bobigny, France
| | - D Valeyre
- Inserm UMR 1272, Sorbonne Paris Nord University, Bobigny, France; Groupe hospitalier Paris Saint Joseph, Pulmonology Departement, Paris, France
| | - F Jeny
- AP-HP, Pulmonology Departement, Avicenne Hospital, Bobigny, France; Inserm UMR 1272, Sorbonne Paris Nord University, Bobigny, France
| |
Collapse
|
2
|
Sesé L, Gille T, Pau G, Dessimond B, Uzunhan Y, Bouvry D, Hervé A, Didier M, Kort F, Freynet O, Rotenberg C, Jeny F, Khamis W, Hindre R, Maesano CN, Planes C, Nunes H, Annesi-Maesano I. Low-cost air quality portable sensors and their potential use in respiratory health. Int J Tuberc Lung Dis 2023; 27:803-809. [PMID: 37880892 DOI: 10.5588/ijtld.23.0197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2023] Open
Abstract
Air pollution is an environmental risk for the general population and for patients with various diseases, particularly respiratory diseases. Little data are available on personal exposure, but the recent emergence of low-cost air quality sensors (LCSs) should enable a better understanding of the health impacts of air pollution at the individual level. However, the reliability and accuracy of most sensors in the market have not been established, and a thorough understanding of their strengths and limitations is needed. We therefore conducted a review to address the following questions: 1) What is an LCS and what is the extent of its possible application? 2) Is the data obtained a reliable indicator of exposure? 3) What are the advantages and disadvantages of LCSs? 4) Could LCSs be useful in investigating the impact of air pollution on respiratory health? Further studies are needed to promote the use of LCS in research settings and among respiratory patients. This will allow us to monitor exposure levels, provide alerts and study the respiratory effects of individual-level air pollution.
Collapse
Affiliation(s)
- L Sesé
- Department of Physiology and Functional Explorations, Assistance Publique-Hôpitaux de Paris (AP-HP), and, Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - T Gille
- Department of Physiology and Functional Explorations, Assistance Publique-Hôpitaux de Paris (AP-HP), and, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - G Pau
- Department of Computer Science and Engineering University of Bologna, Bologna, Italy
| | - B Dessimond
- Institute Desbrest of Epidemiology and Public Health, University of Montpellier and INSERM
| | - Y Uzunhan
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - D Bouvry
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - A Hervé
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - M Didier
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - F Kort
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - O Freynet
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - C Rotenberg
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - F Jeny
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - W Khamis
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - R Hindre
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - C N Maesano
- Department of Computer Science and Engineering University of Bologna, Bologna, Italy
| | - C Planes
- Department of Physiology and Functional Explorations, Assistance Publique-Hôpitaux de Paris (AP-HP), and, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - H Nunes
- Department of Pneumology, Centre Constitutif de Référence des Maladies pulmonaires rares, AP-HP, Hôpital Avicenne, Bobigny, Unité mixte de recherche 1272 'Hypoxia and the Lung', Institut national de la santé et de la recherche médicale (INSERM), Université Sorbonne Paris Nord, Bobigny
| | - I Annesi-Maesano
- Institute Desbrest of Epidemiology and Public Health, University of Montpellier and INSERM, Departement of Allergic and Respiratory Diseases, Montpellier University Hospital, Montpellier, France
| |
Collapse
|
3
|
Olland A, Valeyre D, Nunes H, Le Pavec J. [Lung transplantation for sarcoidosis]. Rev Mal Respir 2023; 40 Suppl 1:e58-e61. [PMID: 36639340 DOI: 10.1016/j.rmr.2022.12.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- A Olland
- Lung Transplantation Group, University Hospital Strasbourg, Strasbourg, France; INSERM (French institute for health and medical research) 1260 Regenerative Nanomedecine, Translational Medicine Federation of Strasbourg, University of Strasbourg, Strasbourg, France
| | - D Valeyre
- Service de Pneumologie, Inserm UMR 1272, Université Sorbonne Paris Nord, AP-HP, Hôpital Avicenne, Bobigny, France; Groupe Hospitalier Paris Saint Joseph, Paris, France
| | - H Nunes
- Service de Pneumologie, Inserm UMR 1272, Université Sorbonne Paris Nord, AP-HP, Hôpital Avicenne, Bobigny, France; Service de Pneumologie, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, Paris, France
| | - J Le Pavec
- Service de Pneumologie et de Transplantation Pulmonaire, Groupe Hospitalier Marie-Lannelongue -Paris Saint Joseph, Le Plessis-Robinson, France; Université Paris-Saclay, Le Kremlin Bicêtre, France; UMR_S 999, Université Paris-Sud, Inserm, Groupe hospitalier Marie-Lannelongue-Saint Joseph, Le Plessis-Robinson, France.
| |
Collapse
|
4
|
Freitas P, Pina A, Carola S, Cardoso C, Gouveia E, Vaz F, Santos M, Mira M, Alexandre M, Miguel I, Brito M, Moreira A, Nunes H. Lobular carcinoma of the breast and response to targeted therapy with CDK4/6 inhibitors – a single Portuguese center experience. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01545-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
5
|
Cottin V, Guéguen S, Nunes H, Jouneau S, Crestani B, Bonniaud P, Wemeau L, Israël-Biet D, Reynaud-Gaubert M, Gondouin A, Cadranel J, Marchand-Adam S, Bramki M, Dufaure-Garé I, Amselem S, Clément A, RaDiCo team. Exemples de partenariats réussis d'une cohorte de maladie rare. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.09.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
6
|
Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Le Guen M, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel P, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex J, Dauriat G, Reynaud-Gaubert M. Transplantation pulmonaire en France : actualisation des indications et contre-indications en 2022. Rev Mal Respir 2022; 39:855-872. [DOI: 10.1016/j.rmr.2022.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 10/18/2022] [Indexed: 11/11/2022]
|
7
|
Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P. [French practical guidelines for the diagnosis and management of IPF - 2021 update, full version]. Rev Mal Respir 2022; 39:e35-e106. [PMID: 35752506 DOI: 10.1016/j.rmr.2022.01.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. METHODS Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients' association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale. RESULTS After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis. CONCLUSION These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis.
Collapse
Affiliation(s)
- V Cottin
- Centre national coordonnateur de référence des maladies pulmonaires rares, service de pneumologie, hôpital Louis-Pradel, Hospices Civils de Lyon (HCL), Lyon, France; UMR 754, IVPC, INRAE, Université de Lyon, Université Claude-Bernard Lyon 1, Lyon, France; Membre d'OrphaLung, RespiFil, Radico-ILD2, et ERN-LUNG, Lyon, France.
| | - P Bonniaud
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie et soins intensifs respiratoires, centre hospitalo-universitaire de Bourgogne et faculté de médecine et pharmacie, université de Bourgogne-Franche Comté, Dijon ; Inserm U123-1, Dijon, France
| | - J Cadranel
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie et oncologie thoracique, Assistance publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, Paris ; Sorbonne université GRC 04 Theranoscan, Paris, France
| | - B Crestani
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie A, AP-HP, hôpital Bichat, Paris, France
| | - S Jouneau
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie, hôpital Pontchaillou, Rennes ; IRSET UMR1085, université de Rennes 1, Rennes, France
| | - S Marchand-Adam
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, hôpital Bretonneau, service de pneumologie, CHRU, Tours, France
| | - H Nunes
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie, AP-HP, hôpital Avicenne, Bobigny ; université Sorbonne Paris Nord, Bobigny, France
| | - L Wémeau-Stervinou
- Centre de référence constitutif des maladies pulmonaires rares, Institut Cœur-Poumon, service de pneumologie et immuno-allergologie, CHRU de Lille, Lille, France
| | - E Bergot
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie et oncologie thoracique, hôpital Côte de Nacre, CHU de Caen, Caen, France
| | - E Blanchard
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie, hôpital Haut Levêque, CHU de Bordeaux, Pessac, France
| | - R Borie
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie A, AP-HP, hôpital Bichat, Paris, France
| | - A Bourdin
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, département de pneumologie et addictologie, hôpital Arnaud-de-Villeneuve, CHU de Montpellier, Montpellier ; Inserm U1046, CNRS UMR 921, Montpellier, France
| | - C Chenivesse
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie et d'immuno-allergologie, hôpital Albert Calmette ; CHRU de Lille, Lille ; centre d'infection et d'immunité de Lille U1019 - UMR 9017, Université de Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, Lille, France
| | - A Clément
- Centre de ressources et de compétence de la mucoviscidose pédiatrique, centre de référence des maladies respiratoires rares (RespiRare), service de pneumologie pédiatrique, hôpital d'enfants Armand-Trousseau, CHU Paris Est, Paris ; Sorbonne université, Paris, France
| | - E Gomez
- Centre de compétence pour les maladies pulmonaires rares, département de pneumologie, hôpitaux de Brabois, CHRU de Nancy, Vandoeuvre-les Nancy, France
| | - A Gondouin
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Jean-Minjoz, Besançon, France
| | - S Hirschi
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, Nouvel Hôpital civil, Strasbourg, France
| | - F Lebargy
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Maison Blanche, Reims, France
| | - C-H Marquette
- Centre de compétence pour les maladies pulmonaires rares, FHU OncoAge, département de pneumologie et oncologie thoracique, hôpital Pasteur, CHU de Nice, Nice cedex 1 ; Université Côte d'Azur, CNRS, Inserm, Institute of Research on Cancer and Aging (IRCAN), Nice, France
| | - D Montani
- Centre de compétence pour les maladies pulmonaires rares, centre national coordonnateur de référence de l'hypertension pulmonaire, service de pneumologie et soins intensifs pneumologiques, AP-HP, DMU 5 Thorinno, Inserm UMR S999, CHU Paris-Sud, hôpital de Bicêtre, Le Kremlin-Bicêtre ; Université Paris-Saclay, Faculté de médecine, Le Kremlin-Bicêtre, France
| | - G Prévot
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Larrey, Toulouse, France
| | - S Quetant
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie et physiologie, CHU Grenoble Alpes, Grenoble, France
| | - M Reynaud-Gaubert
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, AP-HM, CHU Nord, Marseille ; Aix Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France
| | - M Salaun
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, oncologie thoracique et soins intensifs respiratoires & CIC 1404, hôpital Charles Nicole, CHU de Rouen, Rouen ; IRIB, laboratoire QuantiIF-LITIS, EA 4108, université de Rouen, Rouen, France
| | - O Sanchez
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie et soins intensifs, hôpital européen Georges-Pompidou, AP-HP, Paris, France
| | | | - K Berkani
- Clinique Pierre de Soleil, Vetraz Monthoux, France
| | - P-Y Brillet
- Université Paris 13, UPRES EA 2363, Bobigny ; service de radiologie, AP-HP, hôpital Avicenne, Bobigny, France
| | - M Campana
- Service de pneumologie et oncologie thoracique, CHR Orléans, Orléans, France
| | - L Chalabreysse
- Service d'anatomie-pathologique, groupement hospitalier est, HCL, Bron, France
| | - G Chatté
- Cabinet de pneumologie et infirmerie protestante, Caluire, France
| | - D Debieuvre
- Service de pneumologie, GHRMSA, hôpital Emile-Muller, Mulhouse, France
| | - G Ferretti
- Université Grenoble Alpes, Grenoble ; service de radiologie diagnostique et interventionnelle, CHU Grenoble Alpes, Grenoble, France
| | - J-M Fourrier
- Association Pierre-Enjalran Fibrose Pulmonaire Idiopathique (APEFPI), Meyzieu, France
| | - N Just
- Service de pneumologie, CH Victor-Provo, Roubaix, France
| | - M Kambouchner
- Service de pathologie, AP-HP, hôpital Avicenne, Bobigny, France
| | - B Legrand
- Cabinet médical de la Bourgogne, Tourcoing ; Université de Lille, CHU Lille, ULR 2694 METRICS, CERIM, Lille, France
| | - F Le Guillou
- Cabinet de pneumologie, pôle santé de l'Esquirol, Le Pradet, France
| | - J-P Lhuillier
- Cabinet de pneumologie, La Varenne Saint-Hilaire, France
| | - A Mehdaoui
- Service de pneumologie et oncologie thoracique, CH Eure-Seine, Évreux, France
| | - J-M Naccache
- Service de pneumologie, allergologie et oncologie thoracique, GH Paris Saint-Joseph, Paris, France
| | - C Paganon
- Centre national coordonnateur de référence des maladies pulmonaires rares, service de pneumologie, hôpital Louis-Pradel, Hospices Civils de Lyon (HCL), Lyon, France
| | - M Rémy-Jardin
- Institut Cœur-Poumon, service de radiologie et d'imagerie thoracique, CHRU de Lille, Lille, France
| | - S Si-Mohamed
- Département d'imagerie cardiovasculaire et thoracique, hôpital Louis-Pradel, HCL, Bron ; Université de Lyon, INSA-Lyon, Université Claude-Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, Villeurbanne, France
| | | |
Collapse
|
8
|
Bay P, Pineton De Chambrun M, Roux A, Bunel V, Combes A, Israël-Biet D, Zuber B, Nunes H, Allenbach Y, Uzunhan Y. L’assistance extracorporelle en bridge à la transplantation pulmonaire en urgence pour les patients avec une atteinte pulmonaire rapidement progressive d’une dermatomyosite anti-MDA5. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.03.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Bay P, Pineton De Chambrun M, Rothstein V, Mahevas M, Roux A, Zuber B, Israël-Biet D, Hervier B, Tazi A, Mouthon L, Mekinian A, Deligny C, Borie R, Meyer A, Priou P, Savale L, Brillet P, Nunes H, Allenbach Y, Uzunhan Y. Les échanges plasmatiques ne semblent pas être associés à un meilleur pronostic chez les patients avec une atteinte pulmonaire rapidement progressive d’une dermatomyosite anti-MDA5. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.03.288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Sigaux J, Cavalin C, Lescoat A, Brillet PY, Sese L, Nunes H, Boissier MC, Semerano L. OP0006 CLEANING ACTIVITIES, DUSTY CLOTHES LAUNDRY AND TALCUM HANDLING ARE UNDERESTIMATED MAJOR SOURCES OF EXPOSURE TO CRYSTALLINE SILICA IN WOMEN WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundInhalation of crystalline silica (cSiO2) is associated with rheumatoid arthritis (RA). Research on cSiO2 has historically focused on professional exposures and on male workers. However, cSiO2 is ubiquitously present in the environment, substantial exposure can take place in both men and women, in other professional activities and even beyond occupational context.ObjectivesTo identify the main sources of exposure to crystalline silica in a series of RA patients not selected based on their professional activity, and to assess the association between silica exposure and disease features.MethodsThe Dust Exposure Life-Course Questionnaire (DELCQ) is a novel tool that longitudinally quantifies both occupational and non-occupational lifetime exposure to crystalline silica. The DELCQ was previously validated in a representative sample of the general French population that serves as control source for studies in specific diseases. The DELCQ was administered to 97 consecutive patients with RA, exposure scores were compared between cases and age-, sex- and smoking status-matched controls (1:4). The main sources of silica exposure were identified in cases and controls and source-specific exposure levels compared. The association between DELCQ scores and disease variables in cases was tested at uni- and multivariable analysis.ResultsIn women with RA, the main sources of crystalline silica exposure were: cleaning activities, dusty clothes laundry and talcum powder handling, with higher exposure levels from these sources vs. the general population (p<0.005). In the whole series of RA patients, high silica exposure was independently associated with interstitial lung disease (OR 6.5 (95% CI: 1.3 to 32.6)) and mediastinal lymphadenopathy (OR 6.3 (95% CI: 1.4 to 27.7).ConclusionCleaning activities, dusty clothes laundry and talcum handling are underestimated sources of crystalline silica exposure that are overrepresented in women with RA compared to the general population and may contribute to the pathogenesis of the disease.Table 1.Association between occupational silica exposure (by quartile) and HRCT lung abnormalitiesHRCT abnormalityOES(Quartiles)UnadjustedOR (95% CI)AdjustedOR (95% CI)Mediastinal lymphadenopathyQ1-Q3(ref)(ref)Q44.1 (1.2 to 13.9)6.3 (1.4 to 27.7)Interstitial lung diseaseQ1-Q3(ref)(ref)Q46.3 (1.5 to 26.6)6.5 (1.3 to 32.6)EmphysemaQ1-Q3(ref)(ref)Q46.4 (1.6 to 24.7)2.9 (0.6 to 13.7)Abbreviations: OES occupational exposure score. Adjusted OR: adjusted on smoking, sex, disease duration, ACPA and RF status.Disclosure of InterestsNone declared.
Collapse
|
11
|
Tandjaoui-Lambiotte Y, Crockett F, Nunes H, Annesi-Maesano I, Sésé L. Air pollution: the silent killer is also indoors. Int J Tuberc Lung Dis 2022; 26:296-297. [PMID: 35351232 DOI: 10.5588/ijtld.22.0033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- Y Tandjaoui-Lambiotte
- Pulmonology and Infectiology Department, Delafontaine Hospital, Saint Denis, France, Hypoxia & Lung, Institut national de la santé et de la recherche médicale (INSERM) 1272, Bobigny, France, Unité mixte de recherche 1137, INSERM IAME (Infection, Antimicrobiens, Modélisation, Evolution), Paris, France
| | - F Crockett
- Pulmonology and Infectiology Department, Delafontaine Hospital, Saint Denis, France
| | - H Nunes
- Hypoxia & Lung, Institut national de la santé et de la recherche médicale (INSERM) 1272, Bobigny, France, Pulmonology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, Sorbonne Paris Nord University, Bobigny, France
| | - I Annesi-Maesano
- INSERM UA11, Institut Desbrest d´Épidémiologie et de Santé Publique (IDESP), Montpellier University, Montpellier, France
| | - L Sésé
- Hypoxia & Lung, Institut national de la santé et de la recherche médicale (INSERM) 1272, Bobigny, France, Physiology Department, Avicenne Hospital, AP-HP, Bobigny, France, Sorbonne Paris Nord University, Bobigny, France
| |
Collapse
|
12
|
Cottin V, Bonniaud P, Cadranel J, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Crestani B. [Idiopathic pulmonary fibrosis: Update of French practical guidelines]. Rev Mal Respir 2022; 39:193-198. [PMID: 35337709 DOI: 10.1016/j.rmr.2022.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 02/25/2022] [Indexed: 10/18/2022]
Affiliation(s)
- V Cottin
- Service de pneumologie, centre national coordonnateur de référence des maladies pulmonaires rares (OrphaLung), UMR 754, INRAE, hospices civils de Lyon (HCL), université Claude-Bernard Lyon 1, hôpital Louis-Pradel, Lyon, France.
| | - P Bonniaud
- Inserm U123-1, faculté de médecine et pharmacie, centre de référence constitutif des maladies pulmonaires rares, centre hospitalo-universitaire de Bourgogne, université de Bourgogne-Franche Comté, Dijon, France
| | - J Cadranel
- Centre de référence constitutif des maladies pulmonaires rares, Sorbonne université GRC 04 Theranoscan, hôpital Tenon, AP-HP, Paris, France
| | - S Jouneau
- Service de pneumologie, centre de compétence pour les maladies pulmonaires rares de l'adulte, IRSET UMR1085, université de Rennes 1, hôpital Pontchaillou, Rennes, France
| | - S Marchand-Adam
- Service de pneumologie, centre de compétence pour les maladies pulmonaires rares de l'adulte, CHRU, hôpital Bretonneau, Tours, France
| | - H Nunes
- Service de pneumologie, centre de référence constitutif des maladies pulmonaires rares, université Sorbonne Paris Nord, hôpital Avicenne, AP-HP, Bobigny, France
| | - L Wémeau-Stervinou
- Service de pneumologie et immuno-allergologie, centre de référence constitutif des maladies pulmonaires rares, institut Cœur-Poumon, CHU de Lille, Lille, France
| | - B Crestani
- Service de pneumologie A, centre de référence constitutif des maladies pulmonaires rares, université Paris Cité, hôpital Bichat, AP-HP, Paris, France
| |
Collapse
|
13
|
Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P. [French practical guidelines for the diagnosis and management of IPF - 2021 update, short version]. Rev Mal Respir 2022; 39:275-312. [PMID: 35304014 DOI: 10.1016/j.rmr.2022.01.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. METHODS Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients' association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale. RESULTS After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis. CONCLUSION These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis.
Collapse
Affiliation(s)
- V Cottin
- Centre national coordonnateur de référence des maladies pulmonaires rares, service de pneumologie, hôpital Louis-Pradel, Hospices Civils de Lyon (HCL), Lyon, France; UMR 754, IVPC, INRAE, Université de Lyon, Université Claude-Bernard Lyon 1, Lyon, France; Membre d'OrphaLung, RespiFil, Radico-ILD2, et ERN-LUNG, Lyon, France.
| | - P Bonniaud
- Service de pneumologie et soins intensifs respiratoires, centre de référence constitutif des maladies pulmonaires rares, centre hospitalo-universitaire de Bourgogne et faculté de médecine et pharmacie, université de Bourgogne-Franche Comté, Dijon ; Inserm U123-1, Dijon, France
| | - J Cadranel
- Service de pneumologie et oncologie thoracique, centre de référence constitutif des maladies pulmonaires rares, assistance publique-hôpitaux de Paris (AP-HP), hôpital Tenon, Paris ; Sorbonne université GRC 04 Theranoscan, Paris, France
| | - B Crestani
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie A, AP-HP, hôpital Bichat, Paris, France
| | - S Jouneau
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie, hôpital Pontchaillou, Rennes ; IRSET UMR1085, université de Rennes 1, Rennes, France
| | - S Marchand-Adam
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, hôpital Bretonneau, service de pneumologie, CHRU, Tours, France
| | - H Nunes
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie, AP-HP, hôpital Avicenne, Bobigny ; université Sorbonne Paris Nord, Bobigny, France
| | - L Wémeau-Stervinou
- Centre de référence constitutif des maladies pulmonaires rares, Institut Cœur-Poumon, service de pneumologie et immuno-allergologie, CHRU de Lille, Lille, France
| | - E Bergot
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie et oncologie thoracique, hôpital Côte de Nacre, CHU de Caen, Caen, France
| | - E Blanchard
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie, hôpital Haut Levêque, CHU de Bordeaux, Pessac, France
| | - R Borie
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie A, AP-HP, hôpital Bichat, Paris, France
| | - A Bourdin
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, département de pneumologie et addictologie, hôpital Arnaud-de-Villeneuve, CHU de Montpellier, Montpellier ; Inserm U1046, CNRS UMR 921, Montpellier, France
| | - C Chenivesse
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie et d'immuno-allergologie, hôpital Albert Calmette ; CHRU de Lille, Lille ; centre d'infection et d'immunité de Lille U1019 - UMR 9017, Université de Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, Lille, France
| | - A Clément
- Centre de ressources et de compétences de la mucoviscidose pédiatrique, centre de référence des maladies respiratoires rares (RespiRare), service de pneumologie pédiatrique, hôpital d'enfants Armand-Trousseau, CHU Paris Est, Paris ; Sorbonne université, Paris, France
| | - E Gomez
- Centre de compétence pour les maladies pulmonaires rares, département de pneumologie, hôpitaux de Brabois, CHRU de Nancy, Vandoeuvre-les Nancy, France
| | - A Gondouin
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Jean Minjoz, Besançon, France
| | - S Hirschi
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, Nouvel Hôpital civil, Strasbourg, France
| | - F Lebargy
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Maison Blanche, Reims, France
| | - C-H Marquette
- Centre de compétence pour les maladies pulmonaires rares, FHU OncoAge, département de pneumologie et oncologie thoracique, hôpital Pasteur, CHU de Nice, Nice cedex 1 ; Université Côte d'Azur, CNRS, Inserm, Institute of Research on Cancer and Aging (IRCAN), Nice, France
| | - D Montani
- Centre de compétence pour les maladies pulmonaires rares, centre national coordonnateur de référence de l'hypertension pulmonaire, unité pneumologie et soins intensifs pneumologiques, AP-HP, DMU 5 Thorinno, Inserm UMR S999, CHU Paris-Sud, hôpital de Bicêtre, Le Kremlin-Bicêtre ; Université Paris-Saclay, Faculté de médecine, Le Kremlin-Bicêtre, France
| | - G Prévot
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Larrey, Toulouse, France
| | - S Quetant
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie et physiologie, CHU Grenoble Alpes, Grenoble, France
| | - M Reynaud-Gaubert
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, AP-HM, CHU Nord, Marseille ; Aix Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France
| | - M Salaun
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, oncologie thoracique et soins intensifs respiratoires & CIC 1404, hôpital Charles Nicole, CHU de Rouen, Rouen ; IRIB, laboratoire QuantiIF-LITIS, EA 4108, université de Rouen, Rouen, France
| | - O Sanchez
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie et soins intensifs, hôpital européen Georges Pompidou, AP-HP, Paris, France
| | | | - K Berkani
- Clinique Pierre de Soleil, Vetraz Monthoux, France
| | - P-Y Brillet
- Université Paris 13, UPRES EA 2363, Bobigny ; service de radiologie, AP-HP, hôpital Avicenne, Bobigny, France
| | - M Campana
- Service de pneumologie et oncologie thoracique, CHR Orléans, Orléans, France
| | - L Chalabreysse
- Service d'anatomie-pathologique, groupement hospitalier est, HCL, Bron, France
| | - G Chatté
- Cabinet de pneumologie et infirmerie protestante, Caluire, France
| | - D Debieuvre
- Service de Pneumologie, GHRMSA, hôpital Emile Muller, Mulhouse, France
| | - G Ferretti
- Université Grenoble Alpes, Grenoble ; service de radiologie diagnostique et interventionnelle, CHU Grenoble Alpes, Grenoble, France
| | - J-M Fourrier
- Association Pierre Enjalran Fibrose Pulmonaire Idiopathique (APEFPI), Meyzieu, France
| | - N Just
- Service de pneumologie, CH Victor Provo, Roubaix, France
| | - M Kambouchner
- Service de pathologie, AP-HP, hôpital Avicenne, Bobigny, France
| | - B Legrand
- Cabinet médical de la Bourgogne, Tourcoing ; Université de Lille, CHU Lille, ULR 2694 METRICS, CERIM, Lille, France
| | - F Le Guillou
- Cabinet de pneumologie, pôle santé de l'Esquirol, Le Pradet, France
| | - J-P Lhuillier
- Cabinet de pneumologie, La Varenne Saint-Hilaire, France
| | - A Mehdaoui
- Service de pneumologie et oncologie thoracique, CH Eure-Seine, Évreux, France
| | - J-M Naccache
- Service de pneumologie, allergologie et oncologie thoracique, GH Paris Saint-Joseph, Paris, France
| | - C Paganon
- Centre national coordonnateur de référence des maladies pulmonaires rares, service de pneumologie, hôpital Louis-Pradel, Hospices Civils de Lyon (HCL), Lyon, France
| | - M Rémy-Jardin
- Institut Cœur-Poumon, service de radiologie et d'imagerie thoracique, CHRU de Lille, Lille, France
| | - S Si-Mohamed
- Département d'imagerie cardiovasculaire et thoracique, hôpital Louis Pradel, HCL, Bron ; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, Villeurbanne, France
| | | |
Collapse
|
14
|
Assie JB, Chouaid C, Nunes H, Reynaud D, Gaudin AF, Grumberg V, Jolivel R, Jouaneton B, Cotté FE, Duchemann B. 101P Nivolumab outcomes in interstitial lung disease patients with advanced non-small cell lung cancer in French real-world setting. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
15
|
Breillat P, Mariampillai K, Martins P, Legendre P, Dunogue B, Charuel JL, Miyara M, Vanquaethem H, Ackermann F, Benveniste O, Mouthon L, Nunes H, Allenbach Y, Uzunhan Y. POS0323 ANTI PM-SCL ASSOCIATED AUTO IMMUNE DISEASES: MULTICENTRIC COHORT OF 128 PATIENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Autoantibodies permit to classify and subgroup connective tissue diseases (CTD) in homogeneous groups of patients in terms of phenotype and prognosis. Anti PM-Scl antibodies have been associated with different CTD categories such as: idiopathic inflammatory myositis (IIM), systemic sclerosis (SSc), Sjögren’s syndrome (SjS), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD) or undifferentiated connective tissue disease (UCTD).Objectives:To determine clinical spectrum of anti-PM-Scl associated disease and if it an homogenous condition.Methods:This multicentric (four hospitals) observational and retrospective study included all consecutive patients with positive testing for anti PM-Scl antibodies on immunoblot assay and connective tissue disease (2011 -2020). Epidemiological, biological, clinical and radiological data were collected in standard form as well as patient’s outcome.Results:One hundred twenty height patients (female n=96;75%) were included. Median [quartiles] age at diagnosis was 50 [18;84] (IQR) and follow-up duration of 7 [3.75-12] years. Seventy-six (59.3%) patients were simple anti-Pm-Scl positive, and 40.7% were associated with other antibodies: anti-SSA/Ro52 (n=13; 10.92%), SSc associated antibodies (n=21; 16.4%), anti-dsDNA for (n=9; 7%), anti-RNP (n=6; 4.7%) and anti-CCP antibodies (n=6; 4.7%). Most patients had cutaneous involvement (n=106; 83%) with skin thickening (n=47; 36%), mechanics hands (n= 28; 22%), calcinosis (n=26; 20.3%) and subcutaneous edema (n=20; 15.62%). Vascular involvement was frequent with Raynaud phenomenon (n= 89; 69%), telangiectasia (n=36; 28%), skin ulcers (n=27; 21%), pulmonary hypertension (n=8/120; 6.7%) and scleroderma renal crisis (n=2; 1.5%). A majority of patients also displayed an interstitial lung disease (ILD) (n=83; 65.8%); nonspecific interstitial pneumonia (92.7%) and/or organizing pneumonia (25.3%). ILD was characterized by a subacute onset in 37/81 (45.7%); median [quartiles] forced vital capacity (FVC) and total lung capacity (TLC) at diagnosis of 88% [73-105] and 79.5% [68.5-101] respectively. Sixty patients (47%) had muscular sign including myalgia (47%), elevated CPK (n=51; 40%) and muscular weakness (Medical Research Council score <4) (n=19/124;15%). Finally, fifty-three (41.7%) had gastroesophageal reflux. Thirty-nine patients (30.4%) experienced at least one muscular or ILD relapse and 6 (4.84%) died during follow-up (2 breast cancer, 1 pneumonia, 3 unknown etiology). Concerning patients’ prognosis, relapses were associated with skeletal (n=29, 74.4% vs n=32, 35.96%, p < 0.001) or cardiac muscle involvement (n=7, 18.4% vs n=2, 2.5%, p=0.007), and subacute ILD (n=19, 65.5% vs n=18, 34.62%, p= 0.05) with organized pneumonia pattern (n=11, 32.3% vs n=10, 13.9%, p=0.05). Strikingly, ILD occurred mainly in men (90.6% vs 57.2%, p < 0.001) and was associated with anti-Scl-70 positivity (n=14, 16.67% vs 0%, p= 0.01). Muscle involvement was associated arthralgia (n=46, 76.67% vs n=34, 50.75%, p=0.005), respiratory signs at diagnosis: dyspnea NYHA ≥3 (n=46, 75.41% vs n=30, 44.78%, p < 0.001), sub-acute ILD (n=24, 61.54% vs n=13, 30.95%, p=0.0111) with lower FVC (73% [64;88] vs 98 [76;105], p < 0.001). Ulcers were associated with Anti-Scl70 positivity (n=9, 33.33% vs n=5, 4.95%, p < 0.001), Raynaud phenomenon (n=27, 100% vs n=62, 61.39%, p < 0.001), digestive involvement (n=20, 74.07% vs n=34, 33.66%, p < 0.001), ILD with chronic onset (n=15, 78.95% vs n=29, 46.77%, p=0.027) and increased incidence of deaths (n=4, 16% vs n=2, 2.02%, p= 0.01).Conclusion:Conducted on the largest cohort of Anti-PM-Scl patients, this study highlights two main phenotypes that determine different outcome and prognosis. One was associated with muscular disease and subacute onset ILD with more frequent relapses. The second with a vascular phenotype associated with chronic ILD, digestive involvement, chronic evolution and increased incidence of death. This could lead to a reclassification of PM-Scl associated auto immune diseases.Disclosure of Interests:None declared
Collapse
|
16
|
Sese L, Nunes H, Cottin V, Israel-Biet D, Crestani B, Guillot Dudoret S, Cadranel J, Wallaert B, Tazi A, Maître B, Prévot G, Marchand-Adam S, Hirschi S, Dury S, Giraud V, Gondouin A, Bonniaud P, Traclet J, Juvin K, Borie R, Carton Z, Caliez J, Freynet O, Gille T, Planes C, Valeyre D, Uzunhan Y. Gender differences in idiopathic pulmonary fibrosis: Are men and women equal or not? Rev Mal Respir 2021. [DOI: 10.1016/j.rmr.2021.02.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Sese L, Caliez J, Annesi-Maesano I, Cottin V, Pesce G, Didier M, Carton Z, Israel-Biet D, Crestani B, Guillot Dudoret S, Cadranel J, Wallaert B, Tazi A, Maître B, Prévot G, Marchand-Adam S, Hirschi S, Dury S, Giraud V, Gondouin A, Bonniaud P, Traclet J, Juvin K, Borie R, Bernaudin J, Valeyre D, Cavalin C, Nunes H. Low income and progression free survival in idiopathic pulmonary fibrosis: An association to uncover. Rev Mal Respir 2021. [DOI: 10.1016/j.rmr.2021.02.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
18
|
Tandjaoui-Lambiotte Y, Gonzalez F, Boubaya M, Freynet O, Clec H C, Bonnet N, Van Der Meersch G, Oziel J, Huang C, Uzunhan Y, Brillet PY, Poirson F, Martin O, Ahmed P, Ebstein N, Karoubi P, Gaudry S, Nunes H, Cohen Y. Two-year follow-up of 196 interstitial lung disease patients after ICU stay. Int J Tuberc Lung Dis 2021; 25:199-205. [PMID: 33688808 DOI: 10.5588/ijtld.20.0706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE: Interstitial lung diseases (ILDs) are associated with poor prognosis in the intensive care unit (ICU). We aimed to assess factors associated with hospital mortality in ILD patients admitted to the ICU and to investigate long-term outcome.MATERIAL AND METHODS: This was a retrospective study in a teaching hospital specialised in ILD management. Patients with ILD who were hospitalised in the ICU between 2000 and 2014 were included. Independent predictors of hospital mortality were identified using logistic regression.RESULTS: A total of 196 ILD patients were admitted to the ICU during the study period. Overall hospital mortality was 55%. Two years after ICU admission, 70 (36%) patients were still alive. Of the 196 patients, 108 (55%) required invasive mechanical ventilation, of whom 21 (20%) were discharged alive from hospital. Acute exacerbation of ILD and multi-organ failure were highly associated with hospital mortality (OR 5.4, 95% CI 1.9-15.5 and OR 12.6, 95% CI 4.9-32.5, respectively).CONCLUSION: Hospital mortality among ILD patients hospitalised in the ICU was high, but even where invasive mechanical ventilation was required, a substantial number of patients were discharged alive from hospital. Multi-organ failure could lead to major ethical concerns.
Collapse
Affiliation(s)
- Y Tandjaoui-Lambiotte
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, Institut national de la santé et de la recherche médicale (INSERM) Hypoxie & Poumon, Bobigny
| | - F Gonzalez
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny
| | - M Boubaya
- Unité de Recherche Clinique, Hôpital Avicenne, Bobigny
| | - O Freynet
- Service de Pneumologie, Hôpital Avicenne, Bobigny
| | - C Clec H
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny
| | - N Bonnet
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, Université Paris XIII, Sorbonne Paris Cité, Paris
| | - G Van Der Meersch
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny
| | - J Oziel
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny
| | - C Huang
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny
| | - Y Uzunhan
- Institut national de la santé et de la recherche médicale (INSERM) Hypoxie & Poumon, Bobigny, Service de Pneumologie, Hôpital Avicenne, Bobigny, Université Paris XIII, Sorbonne Paris Cité, Paris
| | - P-Y Brillet
- Université Paris XIII, Sorbonne Paris Cité, Paris, Service de Radiologie, Hôpital Avicenne, Bobigny
| | - F Poirson
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny
| | - O Martin
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, Université Paris XIII, Sorbonne Paris Cité, Paris
| | - P Ahmed
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny
| | - N Ebstein
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, Université Paris XIII, Sorbonne Paris Cité, Paris
| | - P Karoubi
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny
| | - S Gaudry
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, Université Paris XIII, Sorbonne Paris Cité, Paris, Unité mixte de Recherche S1155, Remodeling and Repair of Renal Tissue, INSERM, Hôpital Tenon, F-75020, Paris
| | - H Nunes
- Institut national de la santé et de la recherche médicale (INSERM) Hypoxie & Poumon, Bobigny, Service de Pneumologie, Hôpital Avicenne, Bobigny, Université Paris XIII, Sorbonne Paris Cité, Paris
| | - Y Cohen
- Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, Université Paris XIII, Sorbonne Paris Cité, Paris, Unité 942, F-75010, INSERM, Paris, France
| |
Collapse
|
19
|
Cottin V, Bergot E, Bourdin A, Nunes H, Prévot G, Wallaert B, Marchand-Adam S. Expectations about treatment of idiopathic pulmonary fibrosis: Comparative survey of patients, carers and physicians (the RESPIR French survey). Respir Med Res 2021; 79:100811. [PMID: 33618076 DOI: 10.1016/j.resmer.2020.100811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 12/22/2020] [Accepted: 12/27/2020] [Indexed: 10/22/2022]
Abstract
CONTEXT Idiopathic pulmonary fibrosis (IPF) is a severe chronic disease during which anxiety and depression are frequent comorbidities. Better knowledge of patients' expectations is needed to inform an action plan to improve medical care. AIM To describe feelings and expectations of patients suffering from IPF and of their carers about antifibrotic therapy and compare them to what is perceived by their pulmonologist. METHODS National prospective study on practices and perceptions. Specific questionnaires were e-mailed to all 3276 pulmonologists in France who, in turn, invited patients and carers to participate in a survey. RESULTS 147 pulmonologists, 161 patients and 144 carers participated in the survey. The role of the carer was evaluated as "important" or "very important" by more than 90% of participants, i.e. pulmonologists, patients or carers. Inconsistencies between how patients felt and how pulmonologists perceived them were identified: 88% of patients responded that they understood quite well what IPF is (vs. 75% of patients according to pulmonologists); 85.5% of patients said they were determined to fight the disease (vs. 68.0%); 61.7% of patients wanted to be kept informed of potential complications before they occurred (vs. 69.6%) and 81.2% wanted to be involved in therapeutic decisions (vs. 43.1%). Globally, patients had a more positive view of antifibrotic therapies than expected by pulmonologists: 41.5% evaluated their advantages superior to what they had expected (vs. 29.1% of patients according to pulmonologists) and 76.5% had a positive image of the benefits/disadvantages ratio (vs. 62.4%). Although pulmonologists had the impression that they were keeping their patients well-informed about exacerbations, hospital stays and the possible negative evolution of the disease despite antifibrotic therapies, 34.0%, 42.0% and 22.0% of patients respectively declared not being aware of these aspects. CONCLUSION The feelings of patients suffering from IPF regarding their disease and treatment globally proved more positive compared with how pulmonologists perceived them. Taking into account the expectations and needs of patients may allow healthcare professionals to better address their needs and priorities.
Collapse
Affiliation(s)
- V Cottin
- National reference coordinating center for rare lung diseases, pulmonology department, Louis-Pradel hospital, hospices civils de Lyon, UMR754, université de Lyon, université Claude-Bernard Lyon 1, INREA, member of OrphaLung, RespiFil, Radico-ILD, and ERN-LUNG, Lyon, France.
| | - E Bergot
- Pulmonology department, University-affiliated hospital of Caen, Caen, France
| | - A Bourdin
- Pulmonology and addictology department, University-affiliated hospital of Montpellier, Montpellier, France
| | - H Nunes
- Pulmonology department, AP-HP, Avicenne University Hospital, Bobigny, France
| | - G Prévot
- Pulmonology department, Hospital of Toulouse, Toulouse, France
| | - B Wallaert
- Pulmonology and Allergy/immunology department, Regional University-affiliated hospital of Lille, Lille, France
| | - S Marchand-Adam
- Pulmonology department, Regional University-affiliated hospital of Tours, Tours, France
| |
Collapse
|
20
|
Caradec E, Mouren D, Zrounba M, Azoulay LD, Blandin C, Ivanoff S, Levy V, Brillet PY, Nunes H, Uzunhan Y. COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib. Respir Med Res 2020; 79:100799. [PMID: 33242734 PMCID: PMC7647390 DOI: 10.1016/j.resmer.2020.100799] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 10/01/2020] [Accepted: 10/14/2020] [Indexed: 01/20/2023]
Affiliation(s)
- E Caradec
- Centre Constitutif de référence des maladies pulmonaires rares, AP-HP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France
| | - D Mouren
- Centre Constitutif de référence des maladies pulmonaires rares, AP-HP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France
| | - M Zrounba
- Centre Constitutif de référence des maladies pulmonaires rares, AP-HP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France
| | - L-D Azoulay
- Centre Constitutif de référence des maladies pulmonaires rares, AP-HP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France
| | - C Blandin
- Centre Constitutif de référence des maladies pulmonaires rares, AP-HP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France
| | - S Ivanoff
- AP-HP, Hôpital Avicenne, Service d'Hématologie, Bobigny, France
| | - V Levy
- AP-HP, Hôpital Avicenne, Service d'Hématologie, Bobigny, France
| | - P-Y Brillet
- AP-HP, Hôpital Avicenne, Service de Radiologie, Bobigny, France; Université Sorbonne Paris Nord, INSERM U1272, Bobigny, France
| | - H Nunes
- Centre Constitutif de référence des maladies pulmonaires rares, AP-HP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France; Université Sorbonne Paris Nord, INSERM U1272, Bobigny, France
| | - Y Uzunhan
- Centre Constitutif de référence des maladies pulmonaires rares, AP-HP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France; Université Sorbonne Paris Nord, INSERM U1272, Bobigny, France.
| |
Collapse
|
21
|
Cottin V, Guéguen S, Jouneau S, Nunes H, Crestani B, Bonniaud P, Wemeau L, Israël-Biet D, Chevereau M, Dufaure-Garé I, Amselem S, Clément A. Fibrose pulmonaire idiopathique au sein de la cohorte RaDiCo-PID. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.04.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
22
|
Pereira C, Martins-Branco D, Bexiga CV, Monteiro A, Nunes H, Luís A, Gouveia E, Moreira A, Passos M. 1119P Targeted treatment and immunotherapy in older patients with advanced melanoma: A single institution real-life experience. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
23
|
Bejan-Angoulvant T, Naccache JM, Caille A, Borie R, Nunes H, Ferreira M, Cadranel J, Crestani B, Cottin V, Marchand-Adam S. Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial. Respir Med Res 2020; 78:100770. [PMID: 32777737 DOI: 10.1016/j.resmer.2020.100770] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Revised: 05/14/2020] [Accepted: 05/18/2020] [Indexed: 11/20/2022]
Abstract
INTRODUCTION Nonspecific interstitial pneumonia (NSIP) are rare but severe diseases, with high mortality and morbidity, with no effective pharmacological treatment allowing for long-term remission, and therefore no clear therapeutic recommendations. Classic immunosuppressants are used as first-line treatment, with only one third of patients being responders and no clear recommendations exist for the choice of the second-line therapy. The EvER-ILD study is the first one to prospectively evaluate the efficacy and safety of rituximab and mycophenolate mofetil (MMF) versus placebo and MMF in a broad range of NSIP patients that did not respond to a first-line therapy. A pharmacokinetic-pharmacodynamic analysis based on rituximab serum concentrations will allow identification of potential factors associated with therapeutic response and/or adverse effects. METHODS EvER-ILD study is a French multicenter, prospective, randomized, double blind, placebo-controlled, superiority trial. Patients with severe and progressive NSIP non-responding to a first line immunosuppressive treatment will be randomized in 2 groups of treatment: one course of rituximab plus 6 months MMF (RTX-MMF group) and one course of placebo plus 6 months MMF (Placebo-MMF group). The primary outcome is the change in Forced Vital Capacity (FVC, % of predicted) from baseline to 6 months. Several clinical, biological, and quality of life secondary outcomes will be measured at 3, 6 and 12 months. A sample size of 122 patients (61 patients per group) would allow to show a point difference between groups in the change of FVC at 6 months, based on a common standard deviation for FVC change of 8% with a power of 90%, alpha 5% two-sided, and anticipating an extreme 10% drop-out rate. ETHICS AND DISSEMINATION The protocol was approved by the French Research Ethics Committee (CPP Tours Ouest 1 2016-R28) on November 10, 2016, and by the French competent authority (ANSM, reference 160771A-22) on December 1st, 2016. This article refers to protocol V2, dated November 18, 2016. An independent data safety monitoring board will review safety and tolerability data for the duration of the trial. Results will be disseminated via peer reviewed publication and presentation at international conferences. TRIAL REGISTRATION NUMBER NCT02990286 (clinicaltrials.gov), EudraCT 2016-003026-16 (European Medicines agency).
Collapse
Affiliation(s)
- T Bejan-Angoulvant
- Service de Pharmacologie médicale, CHRU de Tours, Hôpital Bretonneau, Université de Tours, Tours, France
| | - J-Marc Naccache
- AP-HP, Hôpital Tenon, service de pneumologie, Site constitutif du centre de référence pour les maladies pulmonaires rares OrphaLung, and Sorbonne Université, Paris, France
| | - A Caille
- Inserm CIC1415, CHRU Tours, Université de Tours, Université de Nantes, SPHERE, U1246, Tours, France
| | - R Borie
- AP-HP, service de pneumologie, centre de compétences pour les maladies pulmonaires rares, Hôpital Bichat, Paris, France
| | - H Nunes
- Service de pneumologie, centre constitutif pour les maladies pulmonaires rares, hôpital Avicenne, CHU Paris Seine-Saint-Denis, Bobigny, France
| | - M Ferreira
- Service de Pneumologie, CHRU de Tours, Centre de compétences des maladies pulmonaires rares de la région Centre, Hôpital Bretonneau, Tours, France; Université de Tours, CEPR Inserm U1100, Tours, France
| | - J Cadranel
- AP-HP, Hôpital Tenon, service de pneumologie, Site constitutif du centre de référence pour les maladies pulmonaires rares OrphaLung, and Sorbonne Université, Paris, France
| | - B Crestani
- AP-HP, service de pneumologie, centre de compétences pour les maladies pulmonaires rares, Hôpital Bichat, Paris, France
| | - V Cottin
- Service de Pneumologie, Centre national coordonnateur de référence des maladies pulmonaires rares, Hôpital Louis Pradel, Hospices civils de Lyon, UMR 754, Université Claude Bernard Lyon 1, Lyon, France
| | - S Marchand-Adam
- Service de Pneumologie, CHRU de Tours, Centre de compétences des maladies pulmonaires rares de la région Centre, Hôpital Bretonneau, Tours, France; Université de Tours, CEPR Inserm U1100, Tours, France.
| |
Collapse
|
24
|
Sesé L, Jeny F, Uzunhan Y, Khamis W, Freynet O, Valeyre D, Bernaudin JF, Annesi-Maesano I, Nunes H. [The effect of air pollution in diffuse interstitial lung disease]. Rev Mal Respir 2020; 37:389-398. [PMID: 32278507 DOI: 10.1016/j.rmr.2020.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Accepted: 02/09/2020] [Indexed: 11/30/2022]
Abstract
Few studies have examined the effects of air pollution in diffuse interstitial lung disease and they have focused on small numbers of patients. Most data are available in idiopathic pulmonary fibrosis and studies suggest that the level of exposure to pollutants may influence the development of acute exacerbations (ozone and NO2), their incidence (NO2), decline in respiratory function (PM10) and death (PM10 and PM2.5). Several studies show an increase in the incidence of rheumatoid arthritis in people living near busy roads. In systemic scleroderma, hypersensitivity pneumonitis and sarcoidosis although negative effects of pollution have been reported the data are insufficient to be conclusive. Nevertheless, the observed effects of air pollution are consistent with those described for other chronic respiratory diseases. Exposure to pollution induces oxidative stress, chronic inflammation and shortening of telomeres, which are all mechanisms described in fibrogenesis. New epidemiological studies are needed with individual measurements of exposure to outdoor and indoor pollution, as well as fundamental studies to clarify the effect of pollution on fibrogenesis.
Collapse
Affiliation(s)
- L Sesé
- Service de pneumologie, hôpital Avicenne, AP-HP, Bobigny, France; EPAR, INSERM UMR-S 1136, Sorbonne Université, Paris, France; Service d'explorations fonctionnelles, AP-HP, hôpital Avicenne, Bobigny, France.
| | - F Jeny
- Service de pneumologie, hôpital Avicenne, AP-HP, Bobigny, France; INSERM 1272 « Réponses cellulaires et fonctionnelles à l'hypoxie », Université Paris 13, Bobigny, France
| | - Y Uzunhan
- Service de pneumologie, hôpital Avicenne, AP-HP, Bobigny, France; INSERM 1272 « Réponses cellulaires et fonctionnelles à l'hypoxie », Université Paris 13, Bobigny, France
| | - W Khamis
- Service de pneumologie, hôpital Avicenne, AP-HP, Bobigny, France
| | - O Freynet
- Service de pneumologie, hôpital Avicenne, AP-HP, Bobigny, France
| | - D Valeyre
- Service de pneumologie, hôpital Avicenne, AP-HP, Bobigny, France; INSERM 1272 « Réponses cellulaires et fonctionnelles à l'hypoxie », Université Paris 13, Bobigny, France
| | - J-F Bernaudin
- Service de pneumologie, hôpital Avicenne, AP-HP, Bobigny, France; INSERM 1272 « Réponses cellulaires et fonctionnelles à l'hypoxie », Université Paris 13, Bobigny, France
| | | | - H Nunes
- Service de pneumologie, hôpital Avicenne, AP-HP, Bobigny, France; INSERM 1272 « Réponses cellulaires et fonctionnelles à l'hypoxie », Université Paris 13, Bobigny, France
| |
Collapse
|
25
|
Taieb D, Chauveau S, Khamis W, de Montmollin N, Sesé L, Duchemann B, Nunes H, Uzunhan Y. [A case of systemic sclerosis]. Rev Mal Respir 2020; 37:341-345. [PMID: 32284205 DOI: 10.1016/j.rmr.2020.02.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Accepted: 02/07/2020] [Indexed: 11/19/2022]
Abstract
In systemic sclerosis, the presence of an anti-RNA polymerase III antibody (ARNpol3) is associated with an increased risk of cancer. The characteristic picture of this serotype includes severe diffuse cutaneous involvement, a high risk of renal scleroderma crisis and a 10 year survival of only around 30%. Pulmonary involvement is less common. We report the case of a woman initially treated for drug-induced acute interstitial lung disease revealing chronic interstitial pneumonia with autoimmune features. The disease evolved in three stages with the occurrence of a rapidly progressive diffuse skin sclerosis with anti-ARNPol3 antibodies in the context of ovarian cancer remission.
Collapse
Affiliation(s)
- D Taieb
- Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France
| | - S Chauveau
- Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France
| | - W Khamis
- Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France
| | - N de Montmollin
- Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France
| | - L Sesé
- Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France
| | - B Duchemann
- Service d'oncologie, hôpital Avicenne, AP-HP, Bobigny, France
| | - H Nunes
- Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France; Inserm UMR 1272, laboratoire « hypoxie et poumon », université Paris 13, Bobigny, France
| | - Y Uzunhan
- Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France; Inserm UMR 1272, laboratoire « hypoxie et poumon », université Paris 13, Bobigny, France.
| |
Collapse
|
26
|
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, Aburto M, Acosta O, Andrews C, Antin-Ozerkis D, Arce G, Arias M, Avdeev S, Barczyk A, Bascom R, Bazdyrev E, Beirne P, Belloli E, Bergna M, Bergot E, Bhatt N, Blaas S, Bondue B, Bonella F, Britt E, Buch K, Burk J, Cai H, Cantin A, Castillo Villegas D, Cazaux A, Cerri S, Chaaban S, Chaudhuri N, Cottin V, Crestani B, Criner G, Dahlqvist C, Danoff S, Dematte D'Amico J, Dilling D, Elias P, Ettinger N, Falk J, Fernández Pérez E, Gamez-Dubuis A, Giessel G, Gifford A, Glassberg M, Glazer C, Golden J, Gómez Carrera L, Guiot J, Hallowell R, Hayashi H, Hetzel J, Hirani N, Homik L, Hope-Gill B, Hotchkin D, Ichikado K, Ilkovich M, Inoue Y, Izumi S, Jassem E, Jones L, Jouneau S, Kaner R, Kang J, Kawamura T, Kessler R, Kim Y, Kishi K, Kitamura H, Kolb M, Kondoh Y, Kono C, Koschel D, Kreuter M, Kulkarni T, Kus J, Lebargy F, León Jiménez A, Luo Q, Mageto Y, Maher T, Makino S, Marchand-Adam S, Marquette C, Martinez R, Martínez M, Maturana Rozas R, Miyazaki Y, Moiseev S, Molina-Molina M, Morrison L, Morrow L, Moua T, Nambiar A, Nishioka Y, Nunes H, Okamoto M, Oldham J, Otaola M, Padilla M, Park J, Patel N, Pesci A, Piotrowski W, Pitts L, Poonyagariyagorn H, Prasse A, Quadrelli S, Randerath W, Refini R, Reynaud-Gaubert M, Riviere F, Rodríguez Portal J, Rosas I, Rossman M, Safdar Z, Saito T, Sakamoto N, Salinas Fénero M, Sauleda J, Schmidt S, Scholand M, Schwartz M, Shapera S, Shlobin O, Sigal B, Silva Orellana A, Skowasch D, Song J, Stieglitz S, Stone H, Strek M, Suda T, Sugiura H, Takahashi H, Takaya H, Takeuchi T, Thavarajah K, Tolle L, Tomassetti S, Tomii K, Valenzuela C, Vancheri C, Varone F, Veeraraghavan S, Villar A, Weigt S, Wemeau L, Wuyts W, Xu Z, Yakusevich V, Yamada Y, Yamauchi H, Ziora D. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8:453-460. [PMID: 32145830 DOI: 10.1016/s2213-2600(20)30036-9] [Citation(s) in RCA: 263] [Impact Index Per Article: 65.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 01/06/2020] [Accepted: 01/16/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis. METHODS The INBUILD trial was a randomised, double-blind, placebo-controlled, parallel group trial done at 153 sites in 15 countries. Participants had an investigator-diagnosed fibrosing ILD other than IPF, with chest imaging features of fibrosis of more than 10% extent on high resolution CT (HRCT), forced vital capacity (FVC) of 45% or more predicted, and diffusing capacity of the lung for carbon monoxide (DLco) of at least 30% and less than 80% predicted. Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD. Participants were randomly assigned 1:1 by means of a pseudo-random number generator to receive nintedanib 150 mg twice daily or placebo for at least 52 weeks. Participants, investigators, and other personnel involved in the trial and analysis were masked to treatment assignment until after database lock. In this subgroup analysis, we assessed the rate of decline in FVC (mL/year) over 52 weeks in patients who received at least one dose of nintedanib or placebo in five prespecified subgroups based on the ILD diagnoses documented by the investigators: hypersensitivity pneumonitis, autoimmune ILDs, idiopathic non-specific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. The trial has been completed and is registered with ClinicalTrials.gov, number NCT02999178. FINDINGS Participants were recruited between Feb 23, 2017, and April 27, 2018. Of 663 participants who received at least one dose of nintedanib or placebo, 173 (26%) had chronic hypersensitivity pneumonitis, 170 (26%) an autoimmune ILD, 125 (19%) idiopathic non-specific interstitial pneumonia, 114 (17%) unclassifiable idiopathic interstitial pneumonia, and 81 (12%) other ILDs. The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis in the overall population (hypersensitivity pneumonitis 73·1 [95% CI -8·6 to 154·8]; autoimmune ILDs 104·0 [21·1 to 186·9]; idiopathic non-specific interstitial pneumonia 141·6 [46·0 to 237·2]; unclassifiable idiopathic interstitial pneumonia 68·3 [-31·4 to 168·1]; and other ILDs 197·1 [77·6 to 316·7]; p=0·41 for treatment by subgroup by time interaction). Adverse events reported in the subgroups were consistent with those reported in the overall population. INTERPRETATION The INBUILD trial was not designed or powered to provide evidence for a benefit of nintedanib in specific diagnostic subgroups. However, its results suggest that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis. FUNDING Boehringer Ingelheim.
Collapse
Affiliation(s)
- Athol U Wells
- National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - Kevin R Flaherty
- Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Kevin K Brown
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - Yoshikazu Inoue
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan
| | - Anand Devaraj
- Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College, London, UK
| | - Luca Richeldi
- Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Teng Moua
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, USA
| | - Bruno Crestani
- Université de Paris, Inserm U1152, APHP, Hôpital Bichat, Centre de reference constitutif pour les maladies pulmonaires rares, Paris, France
| | - Wim A Wuyts
- Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
| | | | - Manuel Quaresma
- Boehringer Ingelheim International, Ingelheim am Rhein, Germany
| | | | | | - Martin Kolb
- McMaster University and St Joseph's Healthcare, Hamilton, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Jeny F, Bernaudin JF, Valeyre D, Nunes H, Planès C, Besnard V. [Is hypoxia a factor in the progression of pulmonary sarcoidosis?]. Rev Mal Respir 2020; 37:214-217. [PMID: 32146058 DOI: 10.1016/j.rmr.2020.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2020] [Accepted: 01/12/2020] [Indexed: 11/15/2022]
Abstract
Sarcoidosis is a systemic granulomatous disease that can reduce life expectancy mainly due to pulmonary fibrosis resulting from granulomatous inflammation The lack of vascularization within pulmonary granulomas suggests that macrophages localized in the center of these structures are hypoxic. Hypoxia signaling pathways are known to be pro-inflammatory and pro-fibrotic in various pathological conditions. Recent data suggest an involvement of the transcription factor hypoxia-inducible factor (HIF) in the pathogenesis of sarcoidosis. This could represent a new research approach for the understanding and therapeutic management of sarcoidosis.
Collapse
Affiliation(s)
- F Jeny
- UMR 1272 hypoxie & poumon, Inserm-université Paris 13, SMBH, Bobigny, France; Service de pneumologie, hôpital Avicenne AP-HP, Bobigny, France.
| | - J-F Bernaudin
- UMR 1272 hypoxie & poumon, Inserm-université Paris 13, SMBH, Bobigny, France; Service de pneumologie, hôpital Avicenne AP-HP, Bobigny, France; Faculté de médecine, Sorbonne université, Paris, France
| | - D Valeyre
- UMR 1272 hypoxie & poumon, Inserm-université Paris 13, SMBH, Bobigny, France; Service de pneumologie, hôpital Avicenne AP-HP, Bobigny, France
| | - H Nunes
- UMR 1272 hypoxie & poumon, Inserm-université Paris 13, SMBH, Bobigny, France; Service de pneumologie, hôpital Avicenne AP-HP, Bobigny, France
| | - C Planès
- UMR 1272 hypoxie & poumon, Inserm-université Paris 13, SMBH, Bobigny, France; Service d'explorations fonctionnelles, hôpital Avicenne AP-HP, Bobigny, France
| | - V Besnard
- UMR 1272 hypoxie & poumon, Inserm-université Paris 13, SMBH, Bobigny, France
| |
Collapse
|
28
|
Ghelfenstein Ferreira T, Herbel S, Mechaï F, Bouchaud O, Izri A, Nunes H, Brun S. Association entre sarcoïdose et cryptococcose ostéoarticulaire. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Duchemann B, Didier M, Pailler MC, Brillet PY, Kambouchner M, Uzunhan Y, Freynet O, Chouahnia K, Zelek L, Nunes H. Le nivolumab peut-il être utilisé dans les fibroses pulmonaires idiopathiques ? Rev Mal Respir 2019; 36:209-213. [DOI: 10.1016/j.rmr.2018.11.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Accepted: 08/07/2018] [Indexed: 10/27/2022]
|
30
|
Justet A, Klay D, Cottin V, Nunes H, Molina Molina M, Reynaud-Gaubert M, Naccache J, Manali E, Froidure A, Wemeau L, Gondouin A, Bonniaud P, Andrejak C, Hirschi S, Stéphane J, Tromeur C, Prevost G, Marchand-Adam S, Gamez A, Kannengiesser C, Van Moorsel C, Crestani B, Borie R. Efficacité et tolérance des traitements anti-fibrosants chez les patients porteurs d’une mutation du complexe telomèrase. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Jouneau S, Gamez A, Traclet J, Nunes H, Marchand-Adam S, Kessler R, Israël-Biet D, Borie R, Strombom I, Scalori A, Crestani B, Valeyre D, Cottin V. Étude observationnelle FAS chez des patients atteints de fibrose pulmonaire idiopathique traités par pirfénidone en vie réelle en France. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
32
|
Calender A, Lim C, Weichhart T, Cottin V, Devouassoux G, Bentaher A, Rollat-Farnier P, Buisson A, Israel-Biet D, Nunes H, Bardel C, Valeyre D, Pacheco Y. Analyse en WHOLE EXOME de 5 familles prédisposées à la sarcoïdose et mise en évidence de mutations délétères dans les voies de régulation de l’autophagie, autour des hubs fonctionnels Rac1 et mTor. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
33
|
Graziani M, Reynaud-Gaubert M, Gomez E, Traclet J, Ahmad K, Bergot E, Bertoletti L, Camara B, Israël-Biet D, Jaïs X, Kiakouama-Maleka L, Marchand-Adam S, Montani D, Nieves A, Nunes H, Piegay F, Wémeau-Stervinou L, Zarza V, Polazzi S, Schott A, Zeghmar S, Humbert M, Nasser M, Cottin V. Hypertension pulmonaire au cours des pneumopathies interstitielles diffuses : relation avec la fonction pulmonaire et effet du traitement de l’hypertension pulmonaire (étude HYPID). Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
34
|
Chauveau S, Goudot F, Brillet P, Soussan M, Freynet O, Meune C, Valeyre D, Nunes H, Bouvry D. Apport de la discussion multidisciplinaire pour le diagnostic de sarcoïdose cardiaque. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
35
|
Rech J, Arnulf B, De Margerie Mellon C, Malphettes M, Vignon M, Lavergne D, Kambouchner M, Meignin V, Bergeron-Lafaurie A, Prevot G, Brillet P, Martinod E, Valeyre D, Jaccard A, Nunes H, Uzunhan Y. Présentation, survie et facteurs de survie de l’amylose respiratoire : une série multicentrique Française de 73 patients. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
36
|
Phillips Houlbracq M, Mal H, Cottin V, Hirschi S, Roux A, Wémeau-Stervinou L, Le Pavec J, Claustre J, Park S, Marchand-Adam S, Froidure A, Lazor R, Naccache J, Jouneau S, Nunes H, Reynaud-Gaubert M, Prevot G, Crestani B, Kannengiesser C, Borie R. Évolution après transplantation pulmonaire pour fibrose chez les patients porteurs d’une mutation du complexe télomérase. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
37
|
Lhote R, Nunes H, Sacré K, Launay D, Mahevas M, Haroche J, Chazal T, Devilliers H, Amoura Z, Annesi-Maesano I, Cohen Aubart F. Éfficacité et tolérance du rituximab dans la sarcoïdose : étude multicentrique de 11 patients et revue de 27 cas de la littérature. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Sgard B, Brillet PY, Bouvry D, Djelbani S, Nunes H, Meune C, Valeyre D, Soussan M. Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis. Clin Radiol 2018; 74:81.e9-81.e18. [PMID: 30482560 DOI: 10.1016/j.crad.2018.09.015] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2018] [Accepted: 09/26/2018] [Indexed: 02/07/2023]
Abstract
AIM To compare combined 2-[18F]-fluoro-2-deoxy-d-glucose (FDG)-positron-emission tomography (PET) and cardiac magnetic resonance imaging (CMR) for the diagnosis and therapy monitoring of cardiac sarcoidosis (CS). MATERIALS AND METHODS Eighty patients with sarcoidosis and a suspicion of CS who underwent PET and CMR were included retrospectively. PET was undertaken after a low-carbohydrate-high-fat diet in all patients using a combined 16-section PET/computed tomography (CT) camera. PET was considered positive (PET+) in cases of focal or multifocal FDG uptake. CMR was considered positive (CMR+) in cases of subepicardial late gadolinium enhancement (LGE). A subgroup of 50 patients (50/80) was monitored during therapy and classified as responders or non-responders. RESULTS Eighty-two percent of patients with PET+ (9/11) also had CMR+ imaging, with good spatial agreement (kappa=0,79; 95% confidence interval [CI]: 0.65-0.94). Twenty-seven percent (22/80) had residual physiological FDG uptake, with a standardised uptake value (SUV) not significantly different compared to the SUV from pathological uptake (6.4 versus 6 respectively, p=0,92). The clinical response was more frequent in patients with baseline PET+ compared to baseline PET- (80% versus 45%, p=0.07). PET findings improved in all cases under treatment (7/7), whereas LGE improved in only 33% of patients (3/9). CONCLUSION Due to high risk of false-positive or undetermined findings, PET might be performed as a second-line study in cases of LGE, to assess inflammatory load. In addition, PET seems suitable to predict and assess response under therapy.
Collapse
Affiliation(s)
- B Sgard
- Department of Nuclear Medicine, Hôpital Avicenne, Paris 13 University, Bobigny, France
| | - P-Y Brillet
- Department of Radiology, Hôpital Avicenne, Paris 13 University, Bobigny, France
| | - D Bouvry
- Department of Pneumology, Hôpital Avicenne, Paris 13 University, Bobigny, France
| | - S Djelbani
- Department of Nuclear Medicine, Hôpital Avicenne, Paris 13 University, Bobigny, France
| | - H Nunes
- Department of Pneumology, Hôpital Avicenne, Paris 13 University, Bobigny, France
| | - C Meune
- Department of Cardiology, Hôpital Avicenne, Paris 13 University, Bobigny, France
| | - D Valeyre
- Department of Pneumology, Hôpital Avicenne, Paris 13 University, Bobigny, France
| | - M Soussan
- Department of Nuclear Medicine, Hôpital Avicenne, Paris 13 University, Bobigny, France.
| |
Collapse
|
39
|
Champtiaux N, Cottin V, Chassagnon G, Chaigne B, Valeyre D, Nunes H, Hachulla E, Launay D, Crestani B, Cazalets C, Jego P, Bussone G, Bérezné A, Guillevin L, Revel MP, Cordier JF, Mouthon L. Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality. Semin Arthritis Rheum 2018; 49:98-104. [PMID: 30409416 DOI: 10.1016/j.semarthrit.2018.10.011] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 09/10/2018] [Accepted: 10/09/2018] [Indexed: 12/11/2022]
Abstract
BACKGROUND The syndrome of combined pulmonary fibrosis and emphysema (CPFE) primarily due to tobacco smoking has been reported in connective tissue disease, but little is known about its characteristics in systemic sclerosis (SSc). METHODS In this retrospective multi-center case-control study, we identified 36 SSc patients with CPFE, and compared them with 72 SSc controls with interstitial lung disease (ILD) without emphysema. RESULTS Rate of CPFE in SSc patients with CT scan was 3.6%, and 7.6% among SSc patients with ILD. CPFE-SSc patients were more likely to be male (75 % vs 18%, p < 0.0001), smokers (83 % vs 33%, p < 0.0001), and to have limited cutaneous SSc (53 % vs 24% p < 0.01) than ILD-SSc controls. No specific autoantibody was significantly associated with CPFE. At diagnosis, CPFE-SSc patients had a greater decrease in carbon monoxide diffusing capacity (DLCO 39 ± 13 % vs 51 ± 12% of predicted value, p < 0.0001) when compared to SSc-ILD controls, whereas lung volumes (total lung capacity and forced vital capacity) were similar. During follow-up, CPFE-SSc patients more frequently developed precapillary pulmonary hypertension (PH) (44 % vs 11%, p < 10-4), experienced more frequent unscheduled hospitalizations (50 % vs 25%, p < 0.01), and had decreased survival (p < 0.02 by Kaplan-Meier survival analysis) as compared to ILD-SSc controls. CONCLUSIONS The CPFE syndrome is a distinct pulmonary manifestation in SSc, with higher morbidity and mortality. Early diagnosis of CPFE by chest CT in SSc patients (especially smokers) may result in earlier smoking cessation, screening for PH, and appropriate management.
Collapse
Affiliation(s)
- N Champtiaux
- Department of Internal Medicine, Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies Systémiques Autoimmunes Rares d'Ile de France, DHU Authors (Autoimmune and Hormonal Diseases), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (AP-HP), 27, rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France
| | - V Cottin
- Service de Pneumologie, Centre National de Référence des maladies pulmonaire rares, Hospices Civils de Lyon, Hôpital Louis Pradel, Groupe d'Etudes et de Recherche sur les Maladies « Orphelines » Pulmonaires (GERM«O»P), Université Claude Bernard Lyon 1, UMR754, Lyon, France
| | | | - B Chaigne
- Department of Internal Medicine, Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies Systémiques Autoimmunes Rares d'Ile de France, DHU Authors (Autoimmune and Hormonal Diseases), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (AP-HP), 27, rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France
| | - D Valeyre
- Service de Pneumologie, APHP, hôpital Avicenne, Université Paris Nord, 93000 Bobigny, France
| | - H Nunes
- Service de Pneumologie, APHP, hôpital Avicenne, Université Paris Nord, 93000 Bobigny, France
| | - E Hachulla
- Université de Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, Service de Médecine Interne, Hôpital Claude Huriez, Centre de Référence pour la Sclérodermie Systémique, FHU IMMInENT, F-59000 Lille, France
| | - D Launay
- Université de Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, Service de Médecine Interne, Hôpital Claude Huriez, Centre de Référence pour la Sclérodermie Systémique, FHU IMMInENT, F-59000 Lille, France
| | - B Crestani
- Service de Pneumologie A, Hôpital Bichat, DHU FIRE, Université Paris Diderot, Paris, France
| | - C Cazalets
- Service de médecine interne, CHU de Rennes, 2, rue Henri-Le-Guilloux, 35000 Rennes, France
| | - P Jego
- Service de médecine interne, CHU de Rennes, 2, rue Henri-Le-Guilloux, 35000 Rennes, France
| | - G Bussone
- Department of Internal Medicine, Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies Systémiques Autoimmunes Rares d'Ile de France, DHU Authors (Autoimmune and Hormonal Diseases), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (AP-HP), 27, rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France
| | - A Bérezné
- Department of Internal Medicine, Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies Systémiques Autoimmunes Rares d'Ile de France, DHU Authors (Autoimmune and Hormonal Diseases), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (AP-HP), 27, rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France
| | - L Guillevin
- Department of Internal Medicine, Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies Systémiques Autoimmunes Rares d'Ile de France, DHU Authors (Autoimmune and Hormonal Diseases), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (AP-HP), 27, rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France
| | - M P Revel
- Service de Radiologie, Hôpital Cochin, France
| | - J F Cordier
- Service de Pneumologie, Centre National de Référence des maladies pulmonaire rares, Hospices Civils de Lyon, Hôpital Louis Pradel, Groupe d'Etudes et de Recherche sur les Maladies « Orphelines » Pulmonaires (GERM«O»P), Université Claude Bernard Lyon 1, UMR754, Lyon, France
| | - L Mouthon
- Department of Internal Medicine, Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies Systémiques Autoimmunes Rares d'Ile de France, DHU Authors (Autoimmune and Hormonal Diseases), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (AP-HP), 27, rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France.
| | | |
Collapse
|
40
|
Chazal T, Didier M, Durrleman J, Combes A, Febvre M, Nunes H, Valeyre D. [Mediastinitis following endobronchial ultrasound-guided transbronchial needle aspiration]. Rev Mal Respir 2018; 35:745-748. [PMID: 30098879 DOI: 10.1016/j.rmr.2018.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2017] [Accepted: 03/20/2018] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure designed to explore mediastinal lymphadenopathy. Its use and indications have increased recently and severe, though rare, complications have been reported. CASE REPORT EBUS-TBNA was performed in a 64-year-old patient presenting with mediastinal lymphadenopathy, probably due to sarcoidosis, but without histological proof. Within hours of the aspiration of subcarinal lymph nodes (station 7), the patient developed fever and dry cough associated with progressive dysphagia and dysphonia that persisted for four weeks. Mediastinitis was diagnosed after a CT-scan revealed a collection in the subcarinal space previously tapped using CT guidance. Intravenous antibiotics were started and both symptoms and the mediastinal collection resolved without need of a surgical procedure. The patient recovered fully. CONCLUSION EBUS-TBNA is associated with a risk of mediastinitis that may manifest as an isolated fever arising within hours of the procedure. The pathogens responsible are usually contaminants from the oropharynx such as Streptococcus sp, probably inoculated directly into the mediastinum during transbronchial needle aspiration. Rapid diagnosis and treatment are necessary in order to reduce morbidity and mortality associated with mediastinitis.
Collapse
Affiliation(s)
- T Chazal
- Service de pneumologie, hôpital Avicenne, 93000 Bobigny, France.
| | - M Didier
- Service de pneumologie, hôpital Avicenne, 93000 Bobigny, France
| | - J Durrleman
- Service de pneumologie, hôpital Avicenne, 93000 Bobigny, France
| | - A Combes
- Service de réanimation médicale, hôpital La Pitié-Salpêtrière, 75013 Paris, France
| | - M Febvre
- Service de pneumologie, hôpital Tenon, 75020 Paris, France
| | - H Nunes
- Service de pneumologie, hôpital Avicenne, 93000 Bobigny, France
| | - D Valeyre
- Service de pneumologie, hôpital Avicenne, 93000 Bobigny, France
| |
Collapse
|
41
|
Mourtada L, Sese L, Brillet P, Bouvry D, Kambouchner M, Valeyre D, Nunes H. Pneumopathies interstitielles diffuses (PID) fibrosantes prédominant aux lobes supérieurs : étiologies, caractéristiques et pronostic. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Calender A, Rollat Farnier P, Buisson A, Bentaher A, Lebecque S, Besnard V, Planes C, Cottin V, Devouassoux G, Nunes H, Israël Biet D, Valeyre D, Bardel C, Roy P, Pacheco Y. Analyse génétique en Whole Exome Sequencing (WES) de 6 familles prédisposées à la sarcoïdose : une grande hétérogénéité génétique mais une focalisation fonctionnelle autour des voies de signalisation de l’autophagie. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Chilles M, Lhote R, Brillet P, Groh M, Puechal X, Cohen-Aubart F, Delbre X, Guilpain P, Barda T, De Boysson H, Duhaut P, Dominique S, Hachulla E, Hamidou M, Subra J, Lifermann F, Fain O, Cohen P, Lhote F, Nunes H, Mathian A, Catherinot E, Terrier B, Le Quellec A, Legendre C, Cottin V, Amoura Z, Couderc L, Diot E, Guillevin L, Tcherakian C. Impact des dilatations des bronches sur les caractéristiques cliniques et le pronostic des vascularites à ANCA : résultats d’une série de 61 patients. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
44
|
Duchemann B, Didier M, Pailler M, Uzunhan Y, Chouahnia K, Zelek L, Nunes H. Les inhibiteurs de PD1 et PDL1 peuvent-ils être utilisés sans risque dans la fibrose pulmonaire idiopathique ? Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Jouneau S, Cottin V, Pestel K, Nunes H. Tolérance de l’association pirfénidone et nintédanib chez des patients atteints de fibrose pulmonaire idiopathique (FPI) : résultats d’une analyse intermédiaire à 12 semaines d’une étude internationale. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Pastré J, Bouvry D, Juvin K, Benattia A, Annesi-Maesano I, Valeyre D, Nunes H, Israël-Biet D. Caractéristiques des granulomatoses associées aux cancers : une étude cas-témoin comparative avec la sarcoïdose. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Kort F, Habibi A, Lionnet F, Stankovic K, Nunes H, Savale L, Menager P, Ayoub F, Antoine M, Cadranel J, Parrot A, Maitre B, Naccache J. Pneumopathies interstitielles kystiques chez des patients drépanocytaires : une série de 11 cas. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Lhote R, Annesi-Maesano I, Cohen-Aubart F, Nunes H, Launay D, Hamidou M, Borie R, Sacre K, Mahevas M, Schleinitz N, Haroche J, Papo T, Amoura Z, Valeyre D. EpiSarc : étude phénotypique des atteintes extrapulmonaires au cours de la sarcoïdose. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Cottin V, Marchand-Adam S, Borie R, Kessler R, Pestel K, Nunes H. Analyse de la tolérance de la pirfénidone chez des patients atteints de fibrose pulmonaire idiopathique (FPI) : résultats poolés à long terme de deux études internationales en vie réelle. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
50
|
Garrigues P, Chapelon-Abric C, Cohen F, Bouvry D, Nunes H, Valeyre D, Cacoub P. Sarcoïdose du sujet âgé : étude rétrospective de 78 cas. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|